The increasing burden of
cardiovascular disease in China has become a major public health problem, and the prevention and treatment of
cardiovascular disease is in urgent need. For the reality of integrated Chinese and Western medicine in the Chinese health care system, we can consider the service ability of
traditional Chinese medicine. Xueshuan Xinmaining
Tablet is a kind of Chinese
patent medicine commonly used in the treatment of recovery stage of
ischemic stroke and
angina pectoris of
coronary heart disease. Based on the data of hospitalized patients covered by national urban basic medical insurance of China Medical Insurance Research Association in 2013, this study evaluated the treatment cost and detailed composition of the cost for the patients with
cerebral infarction and
coronary heart disease treated by Xueshuan Xinmaining
Tablets. At the same time, the differences in disease burden and direct medical expenses among Xueshuan Xinmaining
Tablets group, Western medicine group and another commonly used Chinese
patent medicine group were analyzed. Among the three groups of patients with
cerebral infarction and
coronary heart disease, the hospitalization rates caused by various causes(44.4% and 29.6%) and diseases(20.8% and 5.2%) in Xueshuan Xinmaining
Tablets group were the lowest(all P<0.01), and the number of hospitalization times in half a year was highest in the common Chinese
patent medicine group(all P<0.01). In patients with
cerebral infarction, the median annual total outpatient expenses were 7 476.8, 7 601.8, 15 650.1 yuan respectively in Western medicine group, Xueshuan Xinmaining
Tablets group and the common Chinese
patent medicine group(P<0.01), and the median hospitalization expenses were 11 620.2, 14 988.9, 13 325.6 yuan respectively(P=0.058). In patients with
coronary heart disease, the total outpatient expenses of the three groups were 6 831.4, 10 228.6, 13 132.4 yuan respectively(P<0.01), and the total hospitalization expenses were 13 354.7, 14 911.5, 15 725.3 yuan respectively(P=0.134). The results showed that in patients with
cerebral infarction and
coronary heart disease, the hospitalization rate was lowest in Xueshuan Xinmaining
Tablets group, beneficial to the turnover of hospital beds and full use of hospital medical resources. The total annual outpatient cost of Xueshuan Xinmaining
Tablets group was lower than that of common Chinese
patent medicine group, beneficial to reduce the burden of disease.